Trastuzumab deruxtecan (T-DXd) is an antibody-active molecule conjugate (ADC) with anticancer and antitumor activity, which is composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) coupled to a topoisomerase I inhibitor (DXd). Trastuzumab deruxtecan has an improved effect on the treatment of HER2-positive breast cancer and gastric cancer.

Datopotamab deruxtecan (DS-1062) is a trophoblast cell surface antigen 2 (TROP2)-targeted antibody-drug conjugate (ADC) with antitumor activity. Datopotamab deruxtecan induces significant antibody-dependent cellular cytotoxicity in the presence of peripheral blood lymphocytes and inhibits tumor growth in xenograft models.

Disitamab vedotin (RC-48) is a newly developed antibody-active molecule conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), consisting of hertuzumab coupled to monomethyl auristatin E (MMAE) via a cleavable linker. Disitamab vedotin showed anti-tumor and anti-proliferative activities in gastric cancer cells with different HER-2 expression levels and inhibited the expression of HER-2 protein in gastric cancer cells.

Mirvetuximab soravtansine (IMGN853) is an antibody-drug coupling (ADC) targeting folate receptor alpha (FRα), which inhibits cell growth and enhances the antiproliferative effects of DNA damage, and may be useful in the study of drug-resistant ovarian cancer.

Sacituzumab govitecan (IMMU-132) is a humanized ADC compound targeting Trop-2 with anticancer activity for the study of refractory, locally advanced or metastatic breast cancer and uroepithelial cancer.

Brentuximab vedotin (SGN-35) is a CD30-targeting antibody-active molecule conjugate (ADC) that combines a CD30 monoclonal antibody with the microtubule disrupting agent monomethylauristatin E for the study of lymphoma.

Telisotuzumab vedotin (ABBV-399) is an ADC compound targeting c-Met with antitumor activity, used for research in recurrent squamous cell lung cancer.

Patritumab deruxtecan (HER3-DXd) is an antibody-drug coupling (ADC) targeting HER3 consisting of a fully humanized anti-HER3 IgG1 monoclonal antibody linked via a cleavable tetrapeptide linker to a topoisomerase I inhibitor payload (an ezetiocan derivative, DXd) for the study of non-small cell lung cancer (NSCLC).

Iladatuzumab vedotin (DCDS-0780A) is an ADC compound targeting CD79b, conjugated with the cytotoxic drug MMAE through a cleavable dipeptide linker mc-val-cit-PABC, used in the study of non-Hodgkin lymphoma.

Enfortumab vedotin-ejfv (Padcev) is an ADC compound targeting Nectin-4 with anti-tumor activity, used in the study of urothelial carcinoma.

Glembatumumab vedotin (CDX-011) is an antibody-drug conjugate (ADC) that targets cancer cells expressing transmembrane glycoprotein NMB (GPNMB). Glembatumumab vedotin has potent anticancer effects and can be used in the study of triple negative breast cancer (TNBC).

Clivatuzumab MMAE is an ADC consisting of a humanized monoclonal antibody against MUC1 (mucin) and the anti-mitotic cytotoxin MMAE for pancreatic cancer.

Zolbetuximab MMAE (IMAB362 MMAE) is a compound targeting Claudin 18.2 (CLDN18.2) with anti-cancer activity, used in the study of gastric and pancreatic cancers.

Rosopatamab MMAE (HUJ-591 MMAE) is an ADC consisting of a PSMA-directed antibody (humanized IgG1 monoclonal antibody against PSMA and monomethylauristatin E (MMAE) for prostate cancer research.

Enapotamab vedotin is an investigational antibody-drug conjugate (ADC) specifically targeting the receptor tyrosine kinase AXL. it consists of a monoclonal antibody linked to the potent microtubule-disrupting agent monomethyl auristatin E (MMAE) and demonstrates significant inhibitory potential against high AXL-expressing non-small cell lung cancer (NSCLC), including tumors with resistance to EGFR inhibitors like Osimertinib.

Izeltabart Tapatansine (IMGC-936) is a CHO-expressing humanized next-generation medetonin-based ADC compound targeting ADAM9-expressing tumors, and exhibits cytotoxicity against ADAM9-positive human tumor cell lines for cancer research.

ASG-5ME is a drug-antibody coupling targeting SLC44A4 that shows anti-tumor activity in xenograft models and may be used to study pancreatic and gastric cancer.

Raludotatug deruxtecan (DS-6000) is an ADC compound targeting CDH6 with anti-cancer activity, used in the study of ovarian cancer.

Belantamab mafodotin (GSK2857916) is an antibody-drug conjugate targeting B-cell maturation antigen (BCMA) that enhances immune cell infiltration and activation within tumors and delays tumor growth. It is used in studies of multiple myeloma.

Sacituzumab tirumotecan (SKB264) is an antibody-drug conjugate (ADC) targeting TROP2 (trophoblast cell surface antigen 2), capable of releasing the active payload KL610023 within TROP2-positive tumour cells. an effective topoisomerase I inhibitor that induces DNA damage and leads to cell cycle arrest and apoptosis, for use in non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).

Mirvetuximab-DM4 (M9346A-DM4) is a compound targeting FOLR1 with potential anti-cancer activity. It can be used to synthesize Mirvetuximab soravtansine and study ovarian cancer.

Patritumab-MMAE , an Anti-ERBB3/HER3 Reference Antibody, is produced in CHO cells. This antibody comprises a heavy chain of type huIgG1 and a light chain of type hukappa, with a predicted molecular weight (MW) of 150 kDa.

FZ-AD005 is a DLL3-targeted ADC composed of the novel anti-DLL3 antibody FZ-A038 and a valine-alanine (Val-Ala) dipeptide linker. This compound is used for research in small cell lung cancer.

Tusamitamab-MMAE is an antibody-drug conjugate (ADC) that combines a CEACAM5-targeted antibody with Monomethyl auristatin E (MMAE), designed for research in non-small cell lung cancer.